STATINS AND MYOPATHY: MOLECULAR MECHANISMS
<p>The safety of statin therapy is considered. In particular the reasons of a complication such as myopathy are discussed in detail. The molecular mechanisms of statin myopathy , as well as its risk factors are presented. The role of coenzyme Q10 in the myopathy development and coenzyme Q10 ap...
Main Authors: | O. M. Drapkina, E. M. Chernova, O. N. Korneeva |
---|---|
Format: | Article |
Language: | English |
Published: |
Stolichnaya Izdatelskaya Kompaniya
2015-12-01
|
Series: | Racionalʹnaâ Farmakoterapiâ v Kardiologii |
Subjects: | |
Online Access: | http://www.rpcardio.ru/jour/article/view/472 |
Similar Items
-
MYOPATHY AS A SIDE EFFECT OF STATIN THERAPY: MECHANISMS OF DEVELOPMENT AND PROSPECTS FOR TREATMENT
by: O. M. Drapkina, et al.
Published: (2015-09-01) -
LIPID-LOWERING EFFICACY OF ROSUVASTATIN COMPARED WITH OTHER STATINS
by: A. N. Meshkov
Published: (2015-12-01) -
STATINS IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES: REPETITION OF THE PAST AND OPTIMISM FOR THE FUTURE
by: L. N. Malay
Published: (2015-09-01) -
APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY
by: D. A. Sychev, et al.
Published: (2015-09-01) -
UP TO DATE STATINS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES
by: N. F. Puchin'yan, et al.
Published: (2015-12-01)